Telomerase Immunity in Cancer Vaccination
Author Information
Author(s): Cortez-Gonzalez Xochtil, Zanetti Maurizio
Primary Institution: University of California, San Diego
Hypothesis
Can telomerase peptides generate CTL responses that kill across tumor types?
Conclusion
The study shows that telomerase vaccination can induce specific immune responses in cancer patients.
Supporting Evidence
- Telomerase is over-expressed in over 85% of tumor cells.
- Immunogenic peptides have been identified for five major HLA types.
- Patients with prostate, breast, and lung cancer showed better responses to the vaccine.
Takeaway
This study is about a vaccine that helps the body fight cancer by using a part of a protein called telomerase, which is found in many cancer cells.
Methodology
The study involved immunizing cancer patients with telomerase peptides and monitoring their immune responses.
Limitations
The study primarily involved Phase 1 trials, which limits the ability to assess long-term clinical benefits.
Participant Demographics
Fifteen patients with hormone-resistant prostate cancer, median age 73.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website